Summary sheet
Programme loan comprising venture debt operations eligible under 1.2 Health of the InvestEU Research, Innovation and Digitalisation Window (RIDW).
Programme loan under InvestEU RIDW General Debt aiming at providing venture debt finance to eligible counterparts in all InvestEU eligible countries.
The programme loan meets the InvestEU objectives related to (a) research, development and innovation, (b) financial support to entities employing up to 499 employees, with a particular focus on SMEs, and small mid-cap companies and (c) Social investments, including those supporting the implementation of the European Pillar of Social Rights.
It involves investments for the research, development, validation, manufacturing and market-entry of innovative technologies and services addressing unmet medical and public needs, suitable to strengthen the EU's position in Health. The EIB financing therefore supports investments addressing the market failure and gaps associated with imperfect competition and incomplete markets for very innovative and early-stage technologies and services, and those associated with positive knowledge, social and environmental externalities generation.
The projects to be financed under the sub-operations will help the promoters to implement long-term innovation and commercialisation strategies usually entailing high investment risks. The financing will therefore enhance the promoters' technology edge and capabilities, and support the development and deployment of new technologies and innovative, higher value-added products and services addressing unmet medical and public health needs.
The financing structure is designed to address those high-risk investments, which are requiring long-term capital. A similar financing structure is not available from other market players at comparable terms and/or within the same crucial timeframe. The EIB expertise is also pivotal in quasi-equity transactions, as they involve a highly customised structuring component and frequent monitoring to ensure consistency with policy objectives and implementation milestones.
Final beneficiaries will be requested to comply with applicable national and EU legislation, as appropriate.
Final beneficiaries will be requested to comply with applicable national and EU legislation, as appropriate.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).
Documents
General enquiries and comments
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.
Media enquiries
Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.
Complaints mechanism
Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero tolerance against fraud and corruption
The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.
Related publications